Biovail and Athpharma Terminate Joint Development Agreement
Biovail will retain an ongoing economic interest through a royalty on Athpharma's future net revenues from the products, if and when they are commercialized. Athpharma will also make a cash payment to Biovail as a result of the termination of the agreement. Additionally, Biovail has acquired the option to license certain intellectual property from Athpharma, which would provide future consideration to Athpharma.
The four products being transferred are: Bisochron (bisoprolol), a beta-1 selective beta-blocker chronotherapeutic formulation for the treatment of hypertension, Isochron (isosorbide-5-mononitrate), a long-acting nitrate chronotherapeutic formulation for the treatment of angina, and Hepacol I (pravastatin) and Hepacol II (simvastatin), two liver-selective sustained release statin formulations for the treatment of high cholesterol.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.